CoChat

Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development

Open access
Loryan, Irena, Reichel, Andreas, Feng, Bo, Bundgaard, Christoffer, Shaffer, Christopher, Kalvass, Cory, Bednarczyk, Dallas, Morrison, Denise, Lesuisse, Dominique, Hoppe, Edmund, Terstappen, Georg C., Fischer, Holger, Di, Li, Colclough, Nicola, Summerfield, Scott, Buckley, Stephen T., Maurer, Tristan S., Fridén, Markus · 2022 · Pharmaceutical Research
Cited by 142

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose: More than 15 years have passed since the first description of the unbound brain-to-plasma partition coefficient (K p,uu,brain ) by Prof. Margareta Hammarlund-Udenaes, which was enabled by advancements in experimental methodologies including cerebral microdialysis. Since then, growing knowledge and data continue to support the notion that the unbound (free) concentration of a drug at the site of action, such as the brain, is the driving force for pharmacological responses. Towards this end, K p,uu,brain is the key parameter to obtain unbound brain concentrations from unbound plasma concentrations. Methods: To understand the importance and impact of the K p,uu,brain concept in contemporary drug discovery and development, a survey has been conducted amongst major pharmaceutical companies based in Europe and the USA. Here, we present the results from this survey which consisted of 47 questions addressing: 1) Background information of the companies, 2) Implementation, 3) Application areas, 4) Methodology, 5) Impact and 6) Future perspectives. Results and conclusions: From the responses, it is clear that the majority of the companies (93%) has established a common understanding across disciplines of the concept and utility of K p,uu,brain as compared to other parameters related to brain exposure. Adoption of the K p,uu,brain concept has been mainly driven by individual scientists advocating its application in the various companies rather than by a top-down approach. Remarkably, 79% of all responders describe the portfolio impact of K p,uu,brain implementation in their companies as ‘game-changing’. Although most companies (74%) consider the current toolbox for K p,uu,brain assessment and its validation satisfactory for drug discovery and early development, areas of improvement and future research to better understand human brain pharmacokinetics/pharmacodynamics translation have been identified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11095-022-03246-6

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 155

  1. Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p, u), and K(p, uu). Drug Metab Dispos. 2006;34(2):318–23. · DOI
  2. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25(8):1737–50. · DOI · Paper page
  3. Kalant H. A microdialysis procedure for extraction and isolation of corticosteroids from peripheral blood plasma. Biochem J. 1958;69(1):99–103. · doi:10.1042/bj0690099
  4. Gaddum JH. Push-pull cannulae. J Physiol. 1961;155(suppl):1–28. · doi:10.1113/jphysiol.1961.sp006651
  5. Bito L, Davson H, Levin E, Murray M, Snider N. The concentrations of free amino acids and other electrolytes in cerebrospinal fluid, in vivo dialysate of brain, and blood plasma of the dog. J Neurochem. 1966;13(11):1057–67. · DOI · Paper page
  6. Codd AA. A simple device for microdialysis. J Clin Pathol. 1968;21(1):113–4. · doi:10.1136/jcp.21.1.113
  7. Brand PH, Stansbury R. Improved microdialysis technique. Anal Biochem. 1979;94(1):109–11. · doi:10.1016/0003-2697(79)90798-x
  8. Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. J Clin Invest. 1979;64(1):145–54. · DOI · Paper page
  9. Benveniste H, Huttemeier PC. Microdialysis–theory and application. Prog Neurobiol. 1990;35(3):195–215. · DOI · Paper page
  10. Ekblom M, Hammarlund-Udenaes M, Lundqvist T, Sjoberg P. Potential use of microdialysis in pharmacokinetics: a protein binding study. Pharm Res. 1992;9(1):155–8. · doi:10.1023/a:1018960617549
  11. Elmquist WF, Sawchuk RJ. Application of microdialysis in pharmacokinetic studies. Pharm Res. 1997;14(3):267–88. · DOI · Paper page
  12. Hammarlund-Udenaes M. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev. 2000;45(2–3):283–94. · doi:10.1016/s0169-409x(00)00109-5
  13. Dubey RK, McAllister CB, Inoue M, Wilkinson GR. Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. J Clin Invest. 1989;84(4):1155–9. · doi:10.1172/jci114279
  14. Ekblom M, Gardmark M, Hammarlund-Udenaes M. Estimation of unbound concentrations of morphine from microdialysate concentrations by use of nonlinear regression analysis in vivo and in vitro during steady state conditions. Life Sci. 1992;51(6):449–60. · doi:10.1016/0024-3205(92)90413-j
  15. Ekblom M, Gardmark M, Hammarlund-Udenaes M. Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. Biopharm Drug Dispos. 1993;14(1):1–11. · doi:10.1002/bdd.2510140102
  16. Wang Y, Welty DF. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharm Res. 1996;13(3):398–403. · DOI
  17. Xie R, Hammarlund-Udenaes M. Blood-brain barrier equilibration of codeine in rats studied with microdialysis. Pharm Res. 1998;15(4):570–5. · DOI
  18. Bouw R, Ederoth P, Lundberg J, Ungerstedt U, Nordstrom CH, Hammarlund-Udenaes M. Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. Acta Anaesthesiol Scand. 2001;45(3):390–2. · DOI
  19. Ederoth P, Tunblad K, Bouw R, Lundberg CJ, Ungerstedt U, Nordstrom CH, Hammarlund-Udenaes M. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol. 2004;57(4):427–35. · DOI
  20. Tunblad K, Ederoth P, Gardenfors A, Hammarlund-Udenaes M, Nordstrom CH. Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol Scand. 2004;48(3):294–301. · doi:10.1111/j.0001-5172.2003.0311.x
  21. Bostrom E, Simonsson US, Hammarlund-Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos. 2006;34(9):1624–31. · DOI · Paper page
  22. Bundgaard C, Jorgensen M, Mork A. An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents. J Pharmacol Toxicol Methods. 2007;55(2):214–23. · DOI
  23. Harashima H, Sugiyama Y, Sawada Y, Iga T, Hanano M. Comparison between in-vivo and in-vitro tissue-to-plasma unbound concentration ratios (Kp, f) of quinidine in rats. J Pharm Pharmacol. 1984;36(5):340–2. · DOI
  24. Friden M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos. 2007;35(9):1711–9. · DOI · Paper page
  25. Friden M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem. 2009;52(20):6233–43. · DOI · Paper page
  26. Ooie T, Terasaki T, Suzuki H, Sugiyama Y. Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab Dispos. 1997;25(7):784–9.
  27. Donnan FG. The theory of membrane equilibria. Chem Rev. 1924;1(1):73–90. · DOI · Paper page
  28. Klotz IM. The application of the law of mass action to binding by proteins; interactions with calcium. Arch Biochem. 1946;9:109–17.
  29. Zwolinski BJ, Eyring H, Reese CE. Diffusion and membrane permeability. I. J Phys Colloid Chem. 1949;53(9):1426–53. · DOI
  30. Staverman AJ. Non-equilibrium thermodynamics of membrane processes. Trans Faraday Soc. 1952;48:176–85. · DOI · Paper page
  31. Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother. 1956;11(4):379–93. · DOI · Paper page
  32. Schanker LS. Passage of drugs across body membranes. Pharmacol Rev. 1962;14:501–30.
  33. Bartels E, Podleski TR. Action of nicotine on the electroplax and difference of potency between ionized and unionized forms. BBA - Specialised Section on Biophysical Subjects. 1964;79(3):511–20.
  34. Fenstermacher J, Kaye T. Drug diffusion within the brain. Ann NY Acad Sci. 1988;531:29–39. · DOI · Paper page
  35. Fichtl B, Nieciecki AV, Walter K. Tissue binding versus plasma binding of drugs: general principles and pharmacokinetic consequences. In: Testa B, editor. Advances in Drug Research, vol. 20. Academic Press; 1991. p. 117–66.
  36. Hammarlund-Udenaes M, Paalzow LK, de Lange EC. Drug equilibration across the blood-brain barrier–pharmacokinetic considerations based on the microdialysis method. Pharm Res. 1997;14(2):128–34. · DOI · Paper page
  37. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929–39. · DOI · Paper page
  38. Tillement J-P, Urien S, Chaumet-Riffaud P, Riant P, Bree F, Morin D, Albengres E, Barre J. Blood binding and tissue uptake of drugs Recent advances and perspectives. Fundam Clin Pharmacol. 1988;2(S1):72–87. · doi:10.1111/j.1472-8206.1988.tb00663.x
  39. Bouw MR, Gardmark M, Hammarlund-Udenaes M. Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats–a microdialysis study. Pharm Res. 2000;17(10):1220–7. · DOI
  40. Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos. 2002;23(8):327–38. · DOI · Paper page
  41. Mano Y, Higuchi S, Kamimura H. Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm Drug Dispos. 2002;23(9):351–60. · DOI
  42. Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos. 2007;35(4):660–6. · DOI · Paper page
  43. Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R. Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos. 2009;37(7):1548–56. · DOI · Paper page
  44. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD. Receptor occupancy and brain free fraction. Drug Metab Dispos. 2009;37(4):753–60. · DOI
  45. Hammarlund-Udenaes M. Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol. 2010;106(3):215–20. · DOI
  46. Gupta A, Gillard M, Christophe B, Chatelain P, Massingham R, Hammarlund-Udenaes M. Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. Br J Pharmacol. 2007;151(7):1129–36. · DOI
  47. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. Pharmacokinetics and pharmacodynamics of seven opioids in p-glycoprotein-competent mice: assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther. 2007;323(1):346–55. · DOI · Paper page
  48. Bostrom E, Hammarlund-Udenaes M, Simonsson US. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology. 2008;108(3):495–505. · DOI · Paper page
  49. Bundgaard C, Sveigaard C, Brennum LT, Stensbol TB. Associating in vitro target binding and in vivo CNS occupancy of serotonin reuptake inhibitors in rats: the role of free drug concentrations. Xenobiotica. 2012;42(3):256–65. · DOI
  50. Kahlenberg L. On the nature of the process of osmosis and osmotic pressure with observations concerning dialysis. J Phys Chem. 1905;10(3):141–209. · doi:10.1021/j150075a001
  51. Davis BD, Wood WB Jr. Studies on antibacterial action of sulfonamide drugs. III. Correlation of drug activity with binding to plasma proteins. Proc Soc Exp Biol Med. 1942;51(2):283–5. · doi:10.3181/00379727-51-13938
  52. Hamilton PB, Archibald RM. Dialysis cell for rapid quantitative analytical determination of diffusible components in blood plasma. Ind Eng Chem Anal Ed. 1944;16(2):136–7. · doi:10.1021/i560126a025
  53. Klotz IM. Spectrophotometric investigations of the interactions of proteins with organic anions. J Am Chem Soc. 1946;68(11):2299–304. · DOI
  54. Kurz H, Trunk H, Weitz B. Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneimittelforschung. 1977;27(7):1373–80.
  55. Kariv I, Cao H, Oldenburg KR. Development of a high throughput equilibrium dialysis method. J Pharm Sci. 2001;90(5):580–7. · DOI
  56. Lin TH, Lin JH. Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. J Pharmacol Exp Ther. 1990;253(1):45–50. · DOI
  57. Romer J, Bickel MH. A method to estimate binding constants at variable protein concentrations. J Pharm Pharmacol. 1979;31(1):7–11. · DOI
  58. Kurz H, Fichtl B. Binding of drugs to tissues. Drug Metab Rev. 1983;14(3):467–510. · doi:10.3109/03602538308991397
  59. Summerfield SG, Stevens AJ, Cutler L, del Carmen OM, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther. 2006;316(3):1282–90. · DOI · Paper page
  60. Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007;50(19):4606–15. · DOI · Paper page
  61. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos. 2009;37(4):787–93. · DOI · Paper page
  62. Wan H, Ahman M, Holmen AG. Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. J Med Chem. 2009;52(6):1693–700. · DOI
  63. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE. Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos. 2011;39(7):1270–7. · DOI
  64. Reichel A. Integrated approach to optimizing CNS penetration in drug discovery: from the old to the new paradigm and assessment of drug-transporter interactions. In: Hammarlund-Udenaes M, de Lange ECM, Thorne RG, editors. Drug delivery to the brain: physiological concepts, methodologies and approaches. New York: Springer, New York; 2014. p. 339–74. · DOI
  65. Di L, Rong H, Feng B. Demystifying brain penetration in central nervous system drug discovery. J Med Chem. 2013;56(1):2–12. · DOI · Paper page
  66. Van Peer AP, Belpaire FM, Bogaert MG. Binding of drugs in serum, blood cells and tissues of rabbits with experimental acute renal failure. Pharmacology. 1981;22(2):146–52. · doi:10.1159/000137483
  67. Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther. 1996;277(3):1550–9.
  68. Friden M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos. 2009;37(6):1226–33. · DOI
  69. Loryan I, Friden M, Hammarlund-Udenaes M. The brain slice method for studying drug distribution in the CNS. Fluids Barriers CNS. 2013;10(1):6. · DOI · Paper page
  70. Becker S, Liu X. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos. 2006;34(5):855–61. · DOI
  71. Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos. 2011;39(3):353–62. · DOI · Paper page
  72. Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg W, Vermeulen A, Morrison D, Monshouwer M, Heald D, Hammarlund-Udenaes M. Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery. Pharm Res. 2014;31(8):2203–19. · DOI
  73. Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther. 2011;339(3):935–44. · DOI
  74. Liu X, Ding X, Deshmukh G, Liederer BM, Hop CE. Use of cassette dosing approach to assess brain penetration in drug discovery. Drug Metab Dispos. 2012;40:963–9. · DOI
  75. Loryan I, Melander E, Svensson M, Payan M, Konig F, Jansson B, Hammarlund-Udenaes M. In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy. Mol Psychiatry. 2016;21(11):1527–36. · DOI
  76. Colclough N, Chen K, Johnström P, Fridén M, McGinnity DF. Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery. Drug Discovery Today. 2019;24(5):1067–73. · DOI
  77. Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018;4(6):eaat1719. · DOI · Paper page
  78. Shaffer CL, Osgood SM, Mancuso JY, Doran AC. Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. J Pharm Sci. 2014;103(5):1557–62. · DOI
  79. Liu H, Chen Y, Huang L, Sun X, Fu T, Wu S, Zhu X, Zhen W, Liu J, Lu G, Cai W, Yang T, Zhang W, Yu X, Wan Z, Wang J, Summerfield SG, Dong K, Terstappen GC. Drug distribution into peripheral nerve. J Pharmacol Exp Ther. 2018;365(2):336–45. · DOI
  80. Doran AC, Osgood SM, Mancuso JY, Shaffer CL. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab Dispos. 2012;40(11):2162–73. · DOI
  81. Schou M, Varnäs K, Lundquist S, Nakao R, Amini N, Takano A, Finnema SJ, Halldin C, Farde L. Large variation in brain exposure of reference CNS drugs: a PET study in nonhuman primates. Int J Neuropsychopharmacol. 2015;18(10):pyv036. · DOI
  82. Gustafsson S, Eriksson J, Syvanen S, Eriksson O, Hammarlund-Udenaes M, Antoni G. Combined PET and microdialysis for in vivo estimation of drug blood-brain barrier transport and brain unbound concentrations. Neuroimage. 2017;155:177–86. · DOI
  83. Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M. Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J Cereb Blood Flow Metab. 2012;32(5):874–83. · DOI
  84. Jucaite A, Stenkrona P, Cselényi Z, De Vita S, Buil-Bruna N, Varnäs K, Savage A, Varrone A, Johnström P, Schou M, Davison C, Sykes A, Pilla Reddy V, Hoch M, Vazquez-Romero A, Moein MM, Halldin C, Merchant MS, Pass M, Farde L. Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study. Neuro Oncol. 2021;23(4):687–96. · DOI
  85. Friden M, Wennerberg M, Antonsson M, Sandberg-Stall M, Farde L, Schou M. Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain. EJNMMI Res. 2014;4(1):50. · DOI
  86. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, Passchier J, Ruffo AD. Toward an improved prediction of human in vivo brain penetration. Xenobiotica. 2008;38(12):1518–35. · DOI
  87. Assmus F, Seelig A, Gobbi L, Borroni E, Glaentzlin P, Fischer H. Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates. Eur J Pharm Sci. 2015;79:27–35. · DOI
  88. Luptakova D, Vallianatou T, Nilsson A, Shariatgorji R, Hammarlund-Udenaes M, Loryan I, Andren PE. Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. Mol Psychiatry. 2021;26:7732–45. · DOI
  89. Liu H, Dong K, Zhang W, Summerfield SG, Terstappen GC. Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems. Drug Discov Today. 2018;23(7):1357–72. · DOI
  90. Dolgikh E, Watson IA, Desai PV, Sawada GA, Morton S, Jones TM, Raub TJ. QSAR model of unbound brain-to-plasma partition coefficient, Kp, uu, brain: incorporating P-glycoprotein efflux as a variable. J Chem Inf Model. 2016;56(11):2225–33. · DOI
  91. Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg WH, Vermeulen A, Heald D, Hammarlund-Udenaes M, Wassvik CM. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates. Mol Pharm. 2015;12(2):520–32. · DOI
  92. Chen H, Winiwarter S, Friden M, Antonsson M, Engkvist O. In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms. J Mol Graph Model. 2011;29(8):985–95. · DOI
  93. Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem. 2015;58(6):2584–608. · DOI · Paper page
  94. Li Y, Terstappen GC, Zhang W. Differentiation of human induced pluripotent stem cells (hiPSC) into endothelial-type cells and establishment of an in vitro blood-brain barrier model. Methods Mol Biol. 2021. · DOI
  95. Chaves C, Do TM, Cegarra C, Roudieres V, Tolou S, Thill G, Rocher C, Didier M, Lesuisse D. Non-human primate blood-brain barrier and in vitro brain endothelium: from transcriptome to the establishment of a new model. Pharmaceutics. 2020;12(10):967. · DOI
  96. Heymans M, Sevin E, Gosselet F, Lundquist S, Culot M. Mimicking brain tissue binding in an in vitro model of the blood-brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration. Eur J Pharm Biopharm. 2018;127:453–61. · DOI
  97. Feng B, Doran AC, Di L, West MA, Osgood SM, Mancuso JY, Shaffer CL, Tremaine L, Liras J. Prediction of human brain penetration of P-glycoprotein and breast cancer resistance protein substrates using in vitro transporter studies and animal models. J Pharm Sci. 2018;107(8):2225–35. · DOI
  98. Cecchelli R, Aday S, Sevin E, Almeida C, Culot M, Dehouck L, Coisne C, Engelhardt B, Dehouck MP, Ferreira L. A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells. PLoS One. 2014;9(6):e99733. · DOI · Paper page
  99. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck M-P, Fenart L. Modelling of the blood–brain barrier in drug discovery and development. Nat Rev Drug Discovery. 2007;6(8):650–61. · DOI · Paper page
  100. Reichel A, Begley DJ, Abbott NJ. An overview of in vitro techniques for blood-brain barrier studies. Methods Mol Med. 2003;89:307–24.
  101. Di L, Artursson P, Avdeef A, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennernäs H, Smith DA, Sugano K. The critical role of passive permeability in designing successful drugs. ChemMedChem. 2020;15(20):1862–74. · DOI
  102. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther. 2005;313(3):1254–62. · DOI · Paper page
  103. Culot M, Fabulas-da Costa A, Sevin E, Szorath E, Martinsson S, Renftel M, Hongmei Y, Cecchelli R, Lundquist S. A simple method for assessing free brain/free plasma ratios using an in vitro model of the blood brain barrier. PLoS One. 2013;8(12):e80634. · DOI
  104. Trapa PE, Belova E, Liras JL, Scott DO, Steyn SJ. Insights from an integrated physiologically based pharmacokinetic model for brain penetration. J Pharm Sci. 2016;105(2):965–71. · DOI
  105. Ozgür B, Saaby L, Janfelt C, Langthaler K, Eneberg E, Jacobsen A-M, Badolo L, Montanari D, Brodin B. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: in vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice. Eur J Pharm Biopharm. 2021;169:211–9. · doi:10.1016/j.ejpb.2021.10.006
  106. Uchida Y, Wakayama K, Ohtsuki S, Chiba M, Ohe T, Ishii Y, Terasaki T. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-Glycoprotein substrates in cynomolgus monkeys. J Pharmacol Exp Ther. 2014;350(3):578–88. · DOI
  107. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36(2):268–75. · DOI · Paper page
  108. Sato S, Matsumiya K, Tohyama K, Kosugi Y. Translational CNS steady-state drug disposition model in rats, monkeys, and humans for quantitative prediction of brain-to-plasma and cerebrospinal fluid-to-plasma unbound concentration ratios. AAPS J. 2021;23(4):81. · DOI
  109. He H, Lyons KA, Shen X, Yao Z, Bleasby K, Chan G, Hafey M, Li X, Xu S, Salituro GM, Cohen LH, Tang W. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure. Xenobiotica. 2009;39(9):687–93. · DOI
  110. Vendel E, Rottschäfer V, de Lange ECM. The need for mathematical modelling of spatial drug distribution within the brain. Fluids Barriers CNS. 2019;16(1):12–12. · DOI
  111. Yamamoto Y, Valitalo PA, van den Berg DJ, Hartman R, van den Brink W, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Bakshi S, Aranzana-Climent V, Marchand S, Dahyot-Fizelier C, Couet W, Danhof M, van Hasselt JG, de Lange EC. A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations. Pharm Res. 2017;34(2):333–51. · DOI
  112. Yamamoto Y, Valitalo PA, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, van den Berg DJ, Hartman R, Wong YC, Danhof M, van Hasselt JGC, de Lange ECM. Predicting drug concentration-time profiles in multiple CNS compartments using a comprehensive physiologically-based pharmacokinetic model. CPT Pharmacometrics Syst Pharmacol. 2017;6(11):765–77. · DOI
  113. Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange EC. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J. 2012;14(3):543–53. · DOI
  114. Westerhout J, Danhof M, De Lange EC. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci. 2011;100(9):3577–93. · DOI
  115. Lin JH, Sugiyama Y, Awazu S, Hanano M. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm. 1982;10(6):637–47. · DOI
  116. Gardmark M, Hammarlund-Udenaes M. Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat–pharmacokinetic/pharmacodynamic modelling. Pain. 1998;74(2–3):287–96. · doi:10.1016/s0304-3959(97)00180-2
  117. Gardmark M, Karlsson MO, Jonsson F, Hammarlund-Udenaes M. Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling J Pharm Sci. 1998;87(7):813–20. · doi:10.1021/js980056f
  118. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol. 1999;128(3):563–8. · DOI · Paper page
  119. Bouw MR, Xie R, Tunblad K, Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats–pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol. 2001;134(8):1796–804. · doi:10.1038/sj.bjp.0704406
  120. Gupta A, Jansson B, Chatelain P, Massingham R, Hammarlund-Udenaes M. Quantitative determination of cetirizine enantiomers in guinea pig plasma, brain tissue and microdialysis samples using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(12):1749–57. · doi:10.1002/rcm.1983
  121. Gupta A, Hammarlund-Udenaes M, Chatelain P, Massingham R, Jonsson EN. Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. Biopharm Drug Dispos. 2006;27(6):291–7. · DOI
  122. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos. 2006;34(9):1443–7. · DOI · Paper page
  123. Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab. 2006;7(2):183–203. · DOI · Paper page
  124. Syvanen S, Xie R, Sahin S, Hammarlund-Udenaes M. Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res. 2006;23(4):705–17. · DOI
  125. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res. 2007;24(5):1014–25. · DOI · Paper page
  126. Jeffrey P, Summerfield SG. Challenges for blood-brain barrier (BBB) screening. Xenobiotica. 2007;37(10–11):1135–51. · DOI
  127. Hammarlund-Udenaes M, Bredberg U, Friden M. Methodologies to assess brain drug delivery in lead optimization. Curr Top Med Chem. 2009;9(2):148–62. · DOI
  128. Syvanen S, Lindhe O, Palner M, Kornum BR, Rahman O, Langstrom B, Knudsen GM, Hammarlund-Udenaes M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37(3):635–43. · DOI · Paper page
  129. Cui Y, Lotz R, Rapp H, Klinder K, Himstedt A, Sauer A. Muscle to brain partitioning as measure of transporter-mediated efflux at the rat blood-brain barrier and its implementation into compound optimization in drug discovery. Pharmaceutics. 2019;11(11):595. · DOI
  130. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang S-M, Liu X, Smith QR, Zhang LK, Zamek-Gliszczynski MJ, Consortium IT. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther. 2013;94(1):80–94. · DOI · Paper page
  131. Zhang M-Y, Kerns E, McConnell O, Sonnenberg-Reines J, Zaleska MM, Steven Jacobsen J, Butera J, Kreft A. Brain and plasma exposure profiling in early drug discovery using cassette administration and fast liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2004;34(2):359–68. · doi:10.1016/s0731-7085(03)00523-5
  132. Kitamura A, Okura T, Higuchi K, Deguchi Y. Cocktail-dosing microdialysis study to simultaneously assess delivery of multiple organic-cationic drugs to the brain. J Pharm Sci. 2016;105(2):935–40. · doi:10.1002/jps.24691
  133. Moya ELJ, Vandenhaute E, Rizzi E, Boucau MC, Hachani J, Maubon N, Gosselet F, Dehouck MP. Miniaturization and automation of a human in vitro blood-brain barrier model for the high-throughput screening of compounds in the early stage of drug discovery. Pharmaceutics. 2021;13(6):892. · DOI
  134. Trapa PE, Troutman MD, Lau TY, Wager TT, Maurer TS, Patel NC, West MA, Umland JP, Carlo AA, Feng B, Liras JL. In vitro–in vivo extrapolation of key transporter activity at the blood-brain barrier. Drug Metab Dispos. 2019;47(4):405–11. · DOI
  135. Fischer H, Ullah M, de la Cruz CC, Hunsaker T, Senn C, Wirz T, Wagner B, Draganov D, Vazvaei F, Donzelli M, Paehler A, Merchant M, Yu L. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol. 2020;22(6):819–29. · DOI
  136. Graham TH, Shen HC, Liu W, Xiong Y, Verras A, Bleasby K, Bhatt UR, Chabin RM, Chen D, Chen Q, Garcia-Calvo M, Geissler WM, He H, Lassman ME, Shen Z, Tong X, Tung EC, Xie D, Xu S, Colletti SL, Tata JR, Hale JJ, Pinto S, Shen D-M. The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors. Bioorg Med Chem Lett. 2012;22(1):658–65. · doi:10.1016/j.bmcl.2011.10.060
  137. Braun C, Sakamoto A, Fuchs H, Ishiguro N, Suzuki S, Cui Y, Klinder K, Watanabe M, Terasaki T, Sauer A. Quantification of transporter and receptor proteins in dog brain capillaries and choroid plexus: relevance for the distribution in brain and CSF of selected BCRP and P-gp substrates. Mol Pharm. 2017;14(10):3436–47. · DOI
  138. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther. 2011;339(2):579–88. · DOI
  139. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117(2):333–45. · DOI · Paper page
  140. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161–6. · DOI · Paper page
  141. Fenstermacher J, Patlak C. CNS, CSF, and extradural fluid uptake of various hydrophilic materials in the dogfish. Am J Physiol Regul Integr Comp Physiol. 1977;232(1):R45–53. · doi:10.1152/ajpregu.1977.232.1.r45
  142. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev. 2004;56(12):1825–57. · DOI · Paper page
  143. de Lange ECM. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 2013;40(3):315–26. · DOI · Paper page
  144. Saleh MAA, Loo CF, Elassaiss-Schaap J, De Lange ECM. Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations. J Pharmacokinet Pharmacodyn. 2021;48(5):725–41. · DOI
  145. Fischer H, Senn C, Ullah M, Cantrill C, Schuler F, Yu L. Calculation of an apical efflux ratio from P-Glycoprotein (P-gp) in vitro transport experiments shows an improved correlation with in vivo cerebrospinal fluid measurements in rats: impact on P-gp screening and compound optimization. J Pharmacol Exp Ther. 2021;376(3):322–9. · doi:10.1124/jpet.120.000158
  146. Trünkle C, Lechner C, Korr D, Bouché L, Barak N, Fernández-Montalván A, Süssmuth RD, Reichel A. Concentration dependence of the unbound partition coefficient Kp(uu) and its application to correct for exposure-related discrepancies between biochemical and cellular potency of KAT6A inhibitors. Drug Metab Dispos. 2020;48(7):553–62. · DOI
  147. Mateus A, Gordon LJ, Wayne GJ, Almqvist H, Axelsson H, Seashore-Ludlow B, Treyer A, Matsson P, Lundback T, West A, Hann MM, Artursson P. Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. Proc Natl Acad Sci U S A. 2017;114(30):E6231–9. · DOI · Paper page
  148. Di L, Riccardi K, Tess D. Evolving approaches on measurements and applications of intracellular free drug concentration and Kpuu in drug discovery. Expert Opin Drug Metab Toxicol. 2021;17(7):733–46. · DOI
  149. Orozco CC, Atkinson K, Ryu S, Chang G, Keefer C, Lin J, Riccardi K, Mongillo RK, Tess D, Filipski KJ, Kalgutkar AS, Litchfield J, Scott D, Di L. Structural attributes influencing unbound tissue distribution. Eur J Med Chem. 2020;185:111813. · DOI
  150. Riccardi K, Lin J, Li Z, Niosi M, Ryu S, Hua W, Atkinson K, Kosa RE, Litchfield J, Di L. Novel method to predict in vivo liver-to-plasma K(puu) for OATP substrates using suspension hepatocytes. Drug Metab Dispos. 2017;45(5):576–80. · DOI
  151. Zhang D, Hop C, Patilea-Vrana G, Gampa G, Seneviratne HK, Unadkat JD, Kenny JR, Nagapudi K, Di L, Zhou L, Zak M, Wright MR, Bumpus NN, Zang R, Liu X, Lai Y, Khojasteh SC. Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities. Drug Metab Dispos. 2019;47(10):1122–35. · DOI
  152. Delgado-Lopez PD, Corrales-Garcia EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062–71. · DOI · Paper page
  153. Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, Davies NL, de-Almeida C, Degorce SL, Didelot M, Dishington A, Ducray R, Durant ST, Hassall LA, Holmes J, Hughes GD, MacFaul PA, Mulholland KR, McGuire TM, Ouvry G, Pass M, Robb G, Stratton N, Wang Z, Wilson J, Zhai B, Zhao K, Al-Huniti N. The identification of potent, selective, and orally available inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). J Med Chem. 2018;61(9):3823–41. · DOI
  154. Riches LC, Trinidad AG, Hughes G, Jones GN, Hughes AM, Thomason AG, Gavine P, Cui A, Ling S, Stott J, Clark R, Peel S, Gill P, Goodwin LM, Smith A, Pike KG, Barlaam B, Pass M, O’Connor MJ, Smith G, Cadogan EB. Pharmacology of the ATM Inhibitor AZD0156: potentiation of irradiation and Olaparib responses preclinically. Mol Cancer Ther. 2020;19(1):13–25. · DOI · Paper page
  155. Reddy VP, Sykes A, Colclough N, Durant ST, o Connor LO, Hoch M, Bruna NB, Vita S, Merchant MS, Pass M. Abstract 4868: A preclinical PK/PD model based on a mouse glioblastoma survival model for AZD1390, a novel, brain-penetrant ATM kinase inhibitor, to predict the inhibition of DNA damage response induced by radiation and the human efficacious dose. 2019. · doi:10.1158/1538-7445.am2019-4868

Cited by

See all 142

Metadata

Authors
Loryan, I., Reichel, A., Feng, B., Bundgaard, C., Shaffer, C., Kalvass, C., Bednarczyk, D., Morrison, D., Lesuisse, D., Hoppe, E., Terstappen, G. C., Fischer, H., Di, L., Colclough, N., Summerfield, S., Buckley, S. T., Maurer, T. S., & Fridén, M.
Venue
Pharmaceutical Research
Published
2022-04-11
Volume
39
Issue
7
Pages
1321-1341
ISSN
  • 0724-8741 (ISSN-L)
  • 1573-904X
OpenAlex
W4223488441
Cited by
142
References
6
FWCI
7.62
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
Uppsala University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development. https://app.cochat.ai/papers/10.1007/s11095-022-03246-6
The paper
Loryan, I., Reichel, A., Feng, B., Bundgaard, C., Shaffer, C., Kalvass, C., Bednarczyk, D., Morrison, D., Lesuisse, D., Hoppe, E., Terstappen, G. C., Fischer, H., Di, L., Colclough, N., Summerfield, S., Buckley, S. T., Maurer, T. S., & Fridén, M. (2022). Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development. Pharmaceutical Research. https://doi.org/10.1007/s11095-022-03246-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.